Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Apellis Pharmaceuticals Inc (APLS)
NASDAQ:APLS
RESEARCH TOOLSreports
Apellis Pharmaceuticals (APLS) Stock Price & Analysis
729 Followers
APLS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$19.83 - $94.75
Previous Close$47.64
Volume505.23K
Average Volume (3M)1.34M
Market Cap
$5.80B
Enterprise Value$5.50B
Total Cash (Recent Filing)$351.20M
Total Debt (Recent Filing)$110.93M
Price to Earnings (P/E)-10.6
Beta0.55
Next Earnings
May 02, 2024EPS Estimate
-$0.47Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.48
Shares Outstanding120,581,749
10 Day Avg. Volume1,381,004
30 Day Avg. Volume1,337,617
Standard Deviation0.21
R-Squared0.05
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)29.46
Price to Sales (P/S)39.24
Price to Cash Flow (P/CF)-14.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue14.07
Enterprise Value/Gross Profit14.11
Enterprise Value/Ebitda-10.65
Forecast
1Y Price Target
$83.23Price Target Upside72.89% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
Apellis Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Future Growth PotentialApellis Pharmaceuticals' presence at the 23rd Annual Needham Healthcare Conference, along with the upcoming Phase 3 pivotal readout of Empaveli in IC-MPGN and C3G, suggests potential for future growth and increased investor confidence.
Market AdoptionSyfovre's remarkable sales performance as the first FDA-approved treatment for geographic atrophy is expected to continue, supported by strong demand and increasing recognition from both retinal and non-retina specialists.
Product LeadershipSyfovre is seen as the best-in-class drug for GA, with management confident in its sustained leadership based on efficacy and significant reduction in lesion growth.
Bears Say
Market Share90% of surveyed specialists expect their usage of Syfovre to decrease after the implementation of Izervay's permanent CMS J-code.
Product CompetitionThe new J-code for Izervay is expected to have a clear negative impact on Syfovre's usage.
Regulatory ChallengesThe EU re-examination process for Syfovre has begun, but successful appeals are rare, presenting a challenge for market approval in Europe.
---
Ownership Overview
15.03% Insiders
38.36% Mutual Funds
13.01% Other Institutional Investors
33.60% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
APLS FAQ
What was Apellis Pharmaceuticals Inc’s price range in the past 12 months?
Apellis Pharmaceuticals Inc lowest stock price was $19.83 and its highest was $94.75 in the past 12 months.
What is Apellis Pharmaceuticals Inc’s market cap?
Currently, no data Available
When is Apellis Pharmaceuticals Inc’s upcoming earnings report date?
Apellis Pharmaceuticals Inc’s upcoming earnings report date is May 02, 2024 which is in 7 days.
How were Apellis Pharmaceuticals Inc’s earnings last quarter?
Apellis Pharmaceuticals Inc released its earnings results on Feb 27, 2024. The company reported -$0.73 earnings per share for the quarter, beating the consensus estimate of -$0.731 by $0.001.
Is Apellis Pharmaceuticals Inc overvalued?
According to Wall Street analysts Apellis Pharmaceuticals Inc’s price is currently Undervalued.
Does Apellis Pharmaceuticals Inc pay dividends?
Apellis Pharmaceuticals Inc does not currently pay dividends.
What is Apellis Pharmaceuticals Inc’s EPS estimate?
Apellis Pharmaceuticals Inc’s EPS estimate is -$0.47.
How many shares outstanding does Apellis Pharmaceuticals Inc have?
Apellis Pharmaceuticals Inc has 120,581,750 shares outstanding.
What happened to Apellis Pharmaceuticals Inc’s price movement after its last earnings report?
Apellis Pharmaceuticals Inc reported an EPS of -$0.73 in its last earnings report, beating expectations of -$0.731. Following the earnings report the stock price went down -3.318%.
Which hedge fund is a major shareholder of Apellis Pharmaceuticals Inc?
Among the largest hedge funds holding Apellis Pharmaceuticals Inc’s share is Driehaus Capital Management LLC. It holds Apellis Pharmaceuticals Inc’s shares valued at 29M.
---
Apellis Pharmaceuticals Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$83.23 (72.89% Upside)
$83.23 (72.89% Upside)
Blogger Sentiment
Bullish
APLS Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 2.6M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $5.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 7.9%
Last 30 Days ▼ 7.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-44.76%
12-Months-Change
Fundamentals
Return on Equity
-290.14%
Trailing 12-Months
Asset Growth
3.75%
Trailing 12-Months
Company Description
Apellis Pharmaceuticals Inc
Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which develops novel therapeutic compounds. It develops complement immunotherapies for the treatment of complement-dependent autoimmune and inflammatory diseases through APL-2 product. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA.
---
APLS Company Deck
---
APLS Earnings Call
Q4 2024
0:00 / 0:00
---
APLS Stock 12 Months Forecast
Average Price Target
$83.23
▲(72.89% Upside)
Technical Analysis
Best Analysts Covering APLS
1 Year
1 Year Success Rate
15/23 ratings generated profit
1 Year Average Return
+18.26%
assigned a buy rating 4 months ago
Copying Yigal Nochomovitz's trades and holding each position for 1 Year would result in 65.22% of your transactions generating a profit, with an average return of +18.26% per trade.
---